Core Viewpoint - Soleno Therapeutics, Inc. is under investigation for potential violations of federal securities laws following negative reports about its product Vykat XR, which has led to significant declines in its stock price [1][2]. Group 1: Company Performance - On August 15, 2025, a report by Scorpion Capital labeled Vykat XR as overpriced and potentially unsafe for children, resulting in a stock price drop of $5.73, or approximately 7.41%, from $77.36 to $71.64 [1]. - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in stock price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [2]. Group 2: Management Response - The CEO of Soleno acknowledged a disruption in the launch trajectory of Vykat XR following the negative report from Scorpion Capital, citing a decrease in start forms and an increase in discontinuations for non-serious adverse events [2].

Group 1 - The law firm Kirby McInerney LLP is investigating Paysafe Limited for possible violations of federal securities laws or other unlawful business practices [1] - On November 13, 2025, Paysafe reported its Q3 2025 financial results, missing revenue and EPS estimates due to a last-minute client shutdown that resulted in a several-million-dollar write-down [2] - Following the announcement, Paysafe's share price fell by $2.80, approximately 27.6%, from $10.16 on November 12, 2025, to close at $7.36 on November 13, 2025 [2] Group 2 - Investors who purchased or acquired Paysafe securities and have information regarding the investigation are encouraged to contact Kirby McInerney LLP for further discussion [3] - Kirby McInerney LLP specializes in securities, antitrust, whistleblower, and consumer litigation, with a history of achieving recoveries totaling billions of dollars for shareholders [4]

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for allegedly making materially false and misleading statements regarding the company's Long Island City property and its leasing value as a life-science destination during the specified Class Period from January 27, 2025, to October 27, 2025 [3][7]. Allegation Details - The lawsuit claims that the defendants provided overwhelmingly positive statements while concealing adverse facts about the true state of the Long Island City property [3]. - It is alleged that the company's claims regarding the leasing value of the LIC property were misleading and lacked a reasonable basis, particularly concerning the Megacampus™ strategy [3]. - As a result, the defendants' statements about the company's business, operations, and prospects were materially false and misleading throughout the Class Period [3]. Next Steps for Investors - Investors who purchased or acquired Alexandria shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - There is no cost or obligation for investors to inquire about their legal options [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - Varonis Systems, Inc. is facing a federal securities class action due to allegations of misleading statements and failure to disclose material facts regarding its business performance, particularly in relation to its ability to convert existing customers to its SaaS offering [5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Varonis and reminds investors of the March 9, 2026 deadline to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Varonis and its executives made false statements while concealing adverse facts about the company's ability to convert its customer base, leading to inflated stock prices [5][6]. Group 2: Financial Performance and Stock Impact - On October 28, 2025, Varonis reported a significant miss in Annual Recurring Revenue (ARR) and reduced its full-year guidance due to weaker than expected renewals and conversions [6]. - Following the announcement, Varonis' stock price plummeted from $63.00 to $32.34 per share, a decline of approximately 48.67% in one day [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm that has recovered hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sprouts Farmers Market, Inc. due to allegations of misleading statements regarding the company's growth potential and sales performance, which may have led to inflated stock prices for investors [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Sprouts between June 4, 2025, and October 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Sprouts, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Sprouts and its executives violated federal securities laws by making false and misleading statements about the company's growth potential and consumer behavior [5]. Group 2: Financial Performance and Stock Impact - On October 29, 2025, Sprouts reported a 4.3% decrease in comparable store growth compared to the previous quarter, which was below the company's prior projections [6]. - The company projected a continued reduction in comparable sales growth for the fourth quarter, estimating only 0%-2% growth, and lowered its full-year expectations from 7.5%-9% to 7% [6]. - Following the disappointing financial results, Sprouts' stock price fell by $22.64 per share, opening at $81.91 per share [6].

Core Viewpoint - Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1] Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children, leading to a decline in Soleno's share price by $5.73, or approximately 7.41%, from $77.36 to $71.64 [3] - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [4]

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. for allegedly making false and misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which may have led to investor losses [3][6]. Allegation Details - The lawsuit claims that Freeport did not adequately ensure safety at the Grasberg Block Cave mine, creating a heightened risk of worker fatalities [3]. - It is alleged that the lack of proper safety precautions constituted an undisclosed risk of regulatory, litigation, and reputational issues [3]. - The defendants' statements about Freeport-McMoRan's business and operations were materially false and misleading, lacking a reasonable basis during the relevant times [3]. Next Steps - Investors who purchased Freeport shares between February 15, 2022, and September 24, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][6]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 12, 2026 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics Incorporated for possible violations of federal securities laws and unlawful business practices following a significant stock price drop after an FDA response regarding a new drug application [1][2]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint but required additional evidence of effectiveness before making a favorable benefit-risk assessment. Following this announcement, Corcept's stock price fell by $35.40 per share, a decrease of 50.42%, closing at $34.80 per share [2]. Next Steps - Investors who purchased or acquired Corcept shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. The firm offers consultations without any cost or obligation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases. The firm operates nationwide and handles cases in both federal and state courts [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent Health (ARDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant decline in its stock price due to disappointing results from a clinical trial for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol RZLT [4]. - The company is focused on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, leading to a sharp decline in the company's stock on December 11, 2025 [5]. - The highest dose of ersodetug showed reductions in hypoglycemia events, but these results were not statistically significant compared to the placebo [5]. Group 3: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].